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This study investigated the molecular epidemiology of Acinetobacter baumannii in the University
of Debrecen in relation to antibiotic consumption. Overall and ward-specific antibiotic
consumption was measured by the number of defined daily doses (DDD) per 100 bed-days
between 2002 and 2012. Consumption was analysed against the number of A. baumannii
positive patients per 100 bed-days, number of isolates per positive sample, and proportion of
carbapenem resistant A. baumannii, using time-series analysis. Altogether 160 A. baumannii
isolates from different wards were collected and analysed. Carbapenemase genes blaOXA-23-like,
blaOXA-24-like, blaOXA-48-like, blaOXA-51-like, blaOXA-58-like and integrons were sought by PCR.
Relatedness of isolates was assessed by PFGE. Prevalence and carbapenem resistance of A.
baumannii were statistically associated with carbapenem consumption. Prevalence data followed
carbapenem usage with three quarterly lags (r50.51–0.53, P,0.001), and meropenem and
ertapenem, but not imipenem usage affected prevalence. Colistin usage, in turn, lagged behind
prevalence with one lag (r50.68–0.70, P,0.001). Six clusters were identified; the neurology
ward with the lowest carbapenem consumption was associated with the carbapenem-susceptible
cluster, as well as with the carbapenem-susceptible isolates in the cluster with variable
susceptibility. Wards with high carbapenem usage almost exclusively harboured isolates from
carbapenem-resistant clusters. All clusters were dominated by isolates of one or two wards, but
most wards were represented in multiple clusters. Increases in prevalence and carbapenem
resistance of A. baumannii were associated with usage of meropenem and ertapenem but not of
imipenem, which led to the spread of multiple clones in the University.
INTRODUCTION
Acinetobacter baumannii, the clinically most important
species in the A. baumannii-Acinetobacter calcoaceticus com-
plex, represent a major nosocomial problem, especially due
to the frequency of the multidrug resistant phenotype.
Recently, extensively resistant clones susceptible only to
polymyxins have emerged worldwide, for which even
carbapenems, formerly the drug group of choice against A.
baumannii, remain ineffective (Zarrilli et al., 2004). The
emergence of carbapenem resistance is linked to plasmid-
borne class D BlaOXA-23-like and BlaOXA-58-like carba-
penemases. Though most clinically important A. baumannii
subpopulations harbour a naturally occurring chromosomal
BlaOXA-51-like carbapenemase, this alone is not sufficient
for the carbapenem resistant phenotype (Poirel & Nordmann,
2006; Walther-Rasmussen & Høiby, 2006). These carbapene-
mases are associated with the insertion sequences ISAba-1, -2
and -3 (Karunasagar et al., 2011; Tsakris et al., 2008), and
their production has been linked to certain pandemic clones
(Ansaldi et al., 2011; Merkier et al., 2008; Tsakris et al., 2008;
Villalo´n et al., 2013).
Emerging carbapenem resistance in A. baumannii has been
shown by several authors to be a sequel to third generation
cephalosporin and carbapenem usage (Cisneros & Rodrı´guez-
Ban˜o, 2002; Goel et al., 2011; Iosifidis et al., 2008, Manikal
et al., 2000; Ogutlu et al., 2014). This is attributed both to
acquisition of mechanisms providing carbapenem resistance
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and to spread of carbapenem resistant clones (Goel et al.,
2011; Manikal et al., 2000; Ogutlu et al., 2014; Poirel &
Nordmann, 2006).
The aim of the present study was to investigate the
molecular epidemiology of A. baumannii and its carbape-
nem resistance in a Hungarian tertiary care centre, in
relation to changes in antibiotic consumption.
METHODS
Antibiotic consumption and frequency of Acinetobacter spp.
Quarterly antibiotic consumption [number of defined daily doses
(DDD) per 100 bed-days] used by inpatient departments of the
University was monitored between 2002 and 2012, based on the data
of the University Pharmacy using the MS Excel application ABC Calc
Version 3.0. (Monnet 2006). Department-specific data were collected
between 2004 and 2012 (ICU-specific data were not available).
The annual frequency of Acinetobacter isolations in the University was
characterized by the number of patients positive for A. baumanii per
100 bed-days, the proportion of positive samples of inpatients
yielding A. baumannii, the proportion of A. baumannii among the
isolated Gram-negative aerobic/facultatively anaerobic bacteria, and
by the proportion of A. baumanii isolations out of positive blood
culture samples. Antibiotic resistance data of non-duplicate (from
one patient only the first isolate was considered) isolates were
collected from the database of the Laboratory for Bacteriological
Diagnostics serving the University.
The relationship between antibiotic consumption in the University
and changes in isolation frequency, as well as antibiotic resistance of
Acinetobacter spp., was analysed by linear regression. In the case of
antibiotics where the consumption data showed significant correla-
tion with prevalence or resistance data, after trend removal cross-
correlation analysis was performed using quarterly time lags. The lag
with the highest significant correlation coefficient was considered as
the most probable delay antibiotic consumption precedes or follows
changes in resistance or prevalence; . Out of the available drugs in
the carbapenem group, the effect of imipenem, meropenem and
ertapenem (introduced in 2004) was analysed, as doripenem was
introduced in the year of the beginning of the study period and was
used less than other carbapenems.
Prevalence of carbapenem-susceptible and -resistant A. baumannii at
different wards was compared using a chi-squared test; pairwise
comparisons were performed by means of a Fisher exact test.
Consumption of different antibiotic classes at different wards was
compared by means of a Kruskal–Wallis test. Statistical tests were
performed using PAST 3.0. (Hammer et al., 2001).
Bacterial isolates. A total of 160 isolates were collected between
November 2010 and May 2011 at the University of Debrecen, and the
majority (n5135) of isolates originated from different intensive care
units (ICUs). The carbapenem resistance rate in this collection was
79.4 % (127/160). Most isolates were cultured from bronchial (73/
160), blood (18/160), canule (17/160), wound (14/160) and tube (11/
160) samples. The remaining isolates originated from urine (6/160),
throat (5/160), catheter tip (4/160), decubitus (3/160), pleura (2/160),
sputum (2/160), drain (2/160), abscess (2/160), cerebrospinal fluid (1/
160) and outer ear (1/160). These isolates were chosen randomly; they
represent 31.9 % of all A. baumanii isolates recovered and 46.9 % of
patients infected with A. baumannii during the study period. The
isolates originated from the ICU wards of the first and second
departments of internal medicine (18 isolates from 14 patients, and 14
isolates from 12 patients, respectively), neurology (18 isolates from 13
patients), surgery (19 isolates from 13 patients), pulmonology (53
isolates from 10 patients) and neurosurgery (seven isolates of four
patients), and from the perinatal (14 isolates from six patients) and
paediatric (seven isolates from four patients) ICUs of the department
of paediatrics, as well as from eleven other wards of the University (24
isolates from 22 patients). These represent 17.6 %, 43.8 %, 62.1 %,
23.5 %, 51.0 %, 25.9 %, 25.0 %, 36.9 % and 28.9 % of isolates from the
department, respectively, and 41.2 %, 63.2 %, 81.3 %, 43.3 %, 62.5 %,
28.6 %, 40.0 %, 44.4 % and 37.9 % of all patients from whom A.
baumannii was isolated at the department. All wards with ten or more
A. baumannii-positive patients were represented.
Samples were incubated overnight at 37 uC on blood <and eosin
methylene blue agar plates, and isolates were identified by biochemi-
cal tests and by matrix-assisted laser desorption/ionization time-of-
flight (MALDI-TOF) Biotyper (Bruker Daltronics). Susceptibility to
imipenem, meropenem, piperacillin+tazobactam, colistin, ciproflox-
acin, sumetrolim, doxycycline, tigecycline, amikacin, tobramycin and
gentamicin was determined using the Clinical and Laboratory
Standards Institute (CLSI, 2010 =) disc diffusion method. Isolates were
stored frozen until analysis.
Detection of carbapenemase, aminoglycoside and tetracycline
resistance genes. Isolates were grown overnight at 37 uC on blood
agar. A loopful of bacteria was heated to 98 uC in TE buffer (100 mM
Tris, 10 mM EDTA) for 15 min and centrifuged at 11 000 g for
3 min; the supernatant was used as a template for PCR analysis. Stock
solutions were kept at 270 uC and working solutions were renewed
after every five freeze–thaw cycles.
The carbapenemase genes blaOXA-23-like, blaOXA-24-like, blaOXA-48-like,
blaOXA-51-like and blaOXA-58-like were sought using the methods of
Woodford et al. (2006). The association of blaOXA and the insertion
sequences ISAba-1 was also assessed (Turton et al., 2006).
The genes coding for the aminoglycoside-modifying enzymes aac(3)-
IIa, aac(69)-Ib, ant(29)-Ia, ant(39)-Ia, aph(39)-Ia and aph(39)-VIa
were tested as described previously (Frana et al., 2001; Le´vesque et al.,
1995; Vila et al., 1999). Genes armA, rmtA, rmtB encoding 16S rRNA
methylases were sought using the method reported by Bogaerts et al.
(2007).
Analysis of integrons and integron-associated gene cassettes.
The occurrence of resistance integrons was studied by integrase-
specific PCRs (Mazel et al., 2000). Variable regions were amplified as
described by White et al. (2001). At least two representative
amplimers were purified using the Isolate PCR and gel kit
(Bioline), and sequenced using the Sanger method with primer
walking when necessary. CLC DNA Workbench 4.0 (CLC Bio) was
used to assemble and analyse sequences, and genes were identified by
GenBank (http://www.ncbi.nlm.nih.gov) search. The identity of
integrons with variable regions of the same size was confirmed by
restriction fragment length polymorphism analysis using XbaI,
HindIII and DdeI (Fermentas), as determined by restriction site
analysis of the fully sequenced representatives. Restriction analysis
was performed as recommended by the manufacturer.
Determination of the genotype. Genetic relatedness among isolates
was analysed by PFGE. Plugs were prepared as previously described
(Mo´zes et al., 2014) and digested with with ApaI. A CHEF DRIII
machine (Bio-Rad) was used to separate the fragments in 1 % SeaKem
Gold agarose (Lonza) at 14 uC. Electrophoresis was performed at 6 V
cm21, with a reorientation angle of 120u, and switch times were
ramped between 2 s and 35 s for 20 h. DNA banding patterns were
analysed with the Fingerprinting II software (Bio-Rad) using the Dice
coefficient and the unweighted pair group method with averages
(UPGMA). Setting of optimization and position tolerance was 1 %
%paper no. jmm082818 charlesworth ref: jmm082818&
J. Mo´zes and others
2 Journal of Medical Microbiology 63
and 1.5 % respectively; similarity of at least 90 % was considered as
the threshold of probable genetic relatedness.
RESULTS
Association of prevalence and resistance data
with antibiotic consumption
A. baumannii was isolated from approximately 1 % of all
positive samples submitted during the years 2000 to 2008,
but in 2009 and 2010 a sudden increase in the isolation
rates from all positive samples (to 2.3 % and 2.5 %,
respectively) was detected. A similar increase was found
in positive blood samples (from 1–2 % to 4.4 %). In
parallel, the proportion of carbapenem-resistant isolates
increased from 6.2 % to 63.8 % from 2000 to 2010, and
increased further to 73.0 % in 2011.
The antibiotic consumption of the University showed an
increasing trend from 2006. This was mainly attributable to
the increased consumption of broad-spectrum antibiotics,
third generation cephalosporins, fluoroquinolones and,
from 2008, carbapenems. In cross-correlation analysis,
increases in carbapenem consumption followed the trend
in third generation cephalosporin (r50.63, P,0.001 at the
29 quarterly lag corresponding to the period roughly two
years earlier), but replaced piperacillin+tazobactam usage
(r520.54, P,0.001 at +4 quarterly lag corresponding to
the period a year later). Significant temporal correlation
between carbapenem usage and consumption of other
antibiotic classes was not found, except for polymyxins,
which lagged behind carbapenem usage with five quarterly
lags (slightly more than a year, r50.80, P,0.001).
The prevalence as well as the carbapenem resistance of A.
baumannii showed association with consumption of third
generation cephalosporins, carbapenems and colistin, but
not with any other antibiotic classes. Consumption of third
generation cephalosporins preceded the increase in preval-
ence of A. baumannii among positive samples and among
isolated Gram-negative bacteria with 13 (16 in case of
blood samples) quarterly lags (three to four years; r50.55-
0.77, P,50.001 in all cases), as well as the increase in
prevalence of A. baumannii-positive patients (with 14
quarterly lags, three and a half years; r50.58, P,0.001).
However, this association was indirect, as carbapenem
usage followed the consumption of third generation
cephalosporin with nine quarterly lags (see above).
Increasing carbapenem consumption led to an increase in
prevalence of A. baumannii in all positive samples, as well
as in positive blood samples, with a delay of three quarterly
lags (nine months; r50.53, P,0.001 and r50.51, P,0.001,
respectively). When analysing the increasing prevalence of
A. baumannii among Gram-negative bacteria, the delay was
slightly longer (five quarterly lags; r50.54, P,0.001 and
r50.62, P,0.001, respectively). Increasing prevalence was
not explained by the consumption of any other antibiotic
group tested (fluoroquinolones, piperacillin+tazobactam
or third generation cephalosporins). The effect on the
number of patients with A. baumannii positive culture was
comparable (four quarterly lags; r50.46, P50.002).
Carbapenem resistance of A. baumannii showed a similar
correlation with carbapenem usage, also with a delay of
nine months (r50.43, P50.005 at the 23 quarterly lag),
but not with usage of any other drug classes.
Out of the different carbapenem drugs, meropenem
showed temporal association with prevalence (eight to
four lags; r50.45-0.49, P50.002-0.006) and carbapenem
resistance (eight lags; r50.44, P50.007) of A. baumannii or
with the number of positive patients (two lags; r50.39,
P50.01). Ertapenem showed a similar effect, but with
shorter delays. Prevalence lagged behind ertapenem usage
with one to five quarterly lags (r50.54–0.58, P,0.001),
and carbapenem resistance and the number of positive
patients per 100 bed-days with six (r50.42, P50.009) and
four (r50.56, P,0.001) lags, respectively. These variables
were not influenced by imipenem consumption (Fig. 1 >.).
Increasing colistin consumption followed the increase in
prevalence and carbapenem resistance of A. baumanni with
a delay of one quarterly lag (r50.68-0.70, P,0.001 for
prevalence variables and r50.58, P,0.001 for carbapenem
resistance).
Ward-specific differences in antibiotic
consumption, prevalence and carbapenem
resistance
Examining carbapenem consumption among the wards
with the highest isolation rates of A. baumannii revealed
that usage in the department of surgery and pulmonology
was above the University average, while the first depart-
ment of internal medicine, paediatrics and neurology
consumed fewer carbapenems (Fig. 2 ?). The department of
surgery consumed significantly more carbapenems than
other wards (P50.001–0.018), while the neurology depart-
ment consumed significantly fewer carbapenems than any
other wards analysed (P50.010–0.026).
Meropenem was the most popular carbapenem accounting
for 56.7 % of yearly carbapenem cumulative doses (36.2–
92.5 %), followed by imipenem with 26.9 % (6.8–42.8 %)
and ertapenem with 11.8 % (0–28.7 %). Doripenem usage
was very low (4.6 %; 0–12 % of yearly carbapenem cumu-
lative doses). The preferred carbapenems were different
among wards; meropenem was less preferred in surgery
and pulmonology departments (37.5 % and 33.5 % of all
carbapenem DDDs consumed, respectively) than in other
departments (54.6–89.0 % of all carbapenem DDDs con-
sumed). This difference was significant in all pairwise
comparisons (P50.002–0.041). Ertapenem was popular
both in surgery and pulmonology departments (22.4 % and
29.7 % of all carbapenem DDDs consumed, respectively),
but not in any other departments (0.0–1.3 % of all
carbapenem DDDs consumed; P50.004–0.034). Imipenem
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usage was important in the surgery and paediatric depart-
ments, and doripenem usage was invariably low.
Overall aminoglycoside usage was highest in the pulmo-
nology department (P50.005–0.045 in pairwise compar-
isons), where the isolates harbouring the aminoglycoside
resistance methylase gene armA were relatively frequent
(see below).
Regarding the number of A. baumannii positive patients
per 100 bed-days in each year, different wards (except the
second department of internal medicine) showed similar
trends, with a sharp increase between 2005 and 2010, than
a small decrease in 2011 (Fig. 3@ ).
Carbapenem resistance in A. baumannii was highly
prevalent in the surgery ICU, pulmonology ICU, first
internal medicine ICU, perinatal ICU and neurosurgery
ICU, as well as in other wards, but was significantly lower
in the neurology ICU (P.0.001–P50.002 in pairwise
comparisons), and in the paediatric ICU during the study
period (P50.001–0.029 in pairwise comparisons). Cross-
correlation between ward-specific consumption and pre-
valence/resistance data were not significant.
Resistance genes and integrons
As expected, all isolates carried the chromosomal weak
carbapenemase gene blaOXA-51 and the insertion sequence
ISAba-1. blaOXA-23 and blaOXA-24 were present in 78.1 %
(125/160) and 1.2 % (2/160), respectively, and blaOXA-48
and blaOXA-58 were not detected. Carbapenem susceptible
isolates carried only the blaOXA-51 gene, and carbapenem
resistance was linked to carriage of blaOXA-23 or blaOXA-24.
Genes coding for amikacin resistance, aph(39)-VIa and
aac(69)-Ib, were detected in 90.6 % (145/160) and 56.9 %
(91/160) of the isolates, respectively. aph(39)-Ia was found
in 68.7 % (110/160), ant(39)-Ia in 77.5 % (124/160) of
isolates, and ant(29)-Ia was not detected. Out of the tested
aminoglycoside methylase genes only armA could be
detected (11.9 %, 19/160), and rmtA and rmtB genes were
not present. Two or more aminoglycoside resistance genes
were harboured simultaneously in all isolates. Prevalence of
tetracycline resistance genes tetA, tetB and tetD was 11.9 %
(19/160), 6.9 % (11/160) and 39.4 % (63/160), respectively,
and tetC was not encountered. Isolates carrying tetD were
always positive for tetA as well.
Class I integrons were found in the majority of isolates
(93.7 %, 150/160), and class II and III integrons were not
present.
Identification and characterization of A.
baumannii clusters
PFGE distinguished six clusters (A1, A2, B, C1, C2, D), a
pair of isolates with identical patterns and two isolates with
unique profiles. Clusters A1 and A2, as well as clusters C1
and C2, showed somewhat similar profiles (with similar-
ities of 84.6 % and 86.3 %, respectively).
Cluster A1 contained 26 isolates from 19 patients. The
majority of the isolates originated from the neurology ICU/
stroke ward (15/26) and from the paediatric ICU (7/26).
The isolates of this cluster were carbapenem susceptible,
but uniformly resistant to ciprofloxacin, amikacin and
tobramycin. All isolates harboured the blaOXA-51 gene, the
ISAba-1 sequence and a class I integron with the gene
cassette array aac(69)-Ib; hypothetical protein; blaOXA-20
(In426). The genes aph(39)-Ia, aph(39)-VIa, tetA and tetD
were detected in 76.9 % (20/26), 50.0 % (13/26), 73.0 %
(19/26) and 42.3 % (11/26) of the isolates, respectively.
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Fig. 1. Distribution of use rates of all carbapenems (A), meropenem (B), imipenem (C) and ertapenem (D) between 2002 and
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Fig. 3. Changes in the occurrence of A. baumannii-positive
patients (number of A. baumannii-positive patients per 100 bed-
days) in the different departments.
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Other blaOXA, tetracycline or aminoglycoside resistance
genes were not found in the cluster.
Cluster A2 contained seven isolates from four patients. Six of
the seven isolates in this cluster originated from the surgery
ICU, only one isolate originated from the neurosurgery ICU.
They were found to be susceptible only to doxycycline,
tigecycline and polymyxins showing resistance to all other
antibiotic groups, excepting the neurosurgery isolate. Beside
blaOXA-51, all of them carried the blaOXA-23-like gene. They
were positive for the aph(39)-Ia and aph(39)-VIa genes, but
not for any other aminoglycoside or tetracycline resistance
genes tested. None of the isolates harboured integrons.
Cluster B included 19 isolates from 11 patients. The majority
of the isolates (14/19) in the cluster were originated from
the perinatal ICU, and all tested isolates from the perinatal
ICU belonged to this cluster. Antibiotic susceptibility was
characterized by carbapenem and aminoglycoside resistance.
Both blaOXA-51 and blaOXA-23-like carbapenemases, aph(39)-
Ia, aph(39)-VIa and ant(39)-Ia were detected in all members.
They uniformly carried a class I integron with a gene cassette
array of aac(3)-Ia; hypothetical protein; hypothetical pro-
tein; ant(39)-Ia (In561).
Cluster C1 contained 12 isolates of 10 patients, all except
one from the first internal medicine ICU. Ten isolates were
susceptible to doxycycline, tigecycline and polymyxin-B,
one isolate was susceptible to tigecycline and polymyxin-B,
and one was susceptible only to polymyxins. Genes blaoxa-51-like
with ISAba-1, blaoxa-23-like, ant(39)-Ia and aph(39)-VIa were
identified in all isolates. Other tested resistance genes
(armA, rmtA, rmtB, tetA, tetB, tetC, tetD, tetE) were not
found. All isolates were class I integron positive, and the
gene cassette array in eleven isolates was aac(3)-Ia; hypo-
thetical protein; hypothetical protein; ant(39)-Ia (In561).
Curiously, the remaining isolate carried an integron with a
sole ant(39)-Ib gene (In127).
Cluster C2 contained 29 isolates from 24 patients. The
origin of the isolates was varied, with eleven, six, six and
two isolates from the surgery ICU, neurosurgery ICU,
neurology ICU/stroke and first internal medicine ICU
departments, respectively, and the remaining four isolates
from four other wards. Antibiotic susceptibility was highly
diverse within the cluster; while all isolates from neurology
were susceptible to carbapenems, isolates from other
departments showed susceptibility only to doxycycline,
tigecycline and polymyxins or only to polymyxins. The
resistance gene pattern was similar to that of isolates of
cluster C1 except the blaoxa-23-like gene, which was absent in
the six carbapenem susceptible isolates from neurology.
The class I integron carried by all isolates was also identical
to that found in Cluster 1.
Cluster D included 63 isolates, 50 of which originated from
the pulmonology ICU, the other 13 isolates were from
different wards of the second internal medicine department
(eight isolates), first internal medicine ICU (three isolates),
surgery ICU (two isolates) and various other wards (three
isolates). The majority of the isolates were resistant to all
drugs except polymyxins and tigecycline. Isolates within this
cluster had the highest number of resistance genes; all isolates
carried blaoxa-23-like, blaoxa-51-like and ISAba-1, aac(69)-Ib,
aph(39)-Ia, ant(39)-Ia, aph(39)-VIa, aac(39)-Ia and tetB
genes. Moreover, 30.2 % (19/63) of the isolates in the cluster
carried a 16S rRNA methylase gene armA. All isolates carried
a class I integron with a variable region containing aac(69)-Ib;
catB8; ant(39)-Ia gene cassette array (In439). Curiously, the
integrase gene of this integron was not amplifiable with the
primers widely used to detect class I integrase.
Four isolates did not belong to any cluster. One from the
surgery ICU was similar to cluster A2 (showing a similarity
of 86.6 %), but carried an additional aac(69)-Ib gene. An
identical pair of isolates from different departments
(pulmonology ICU and first internal medicine ICU)
showed extensive drug resistance (susceptible only to tigecy-
cline and colistin). These two isolates carried blaoxa-24-like
carbapenemase besides blaoxa-51-like and ISAba-1, but none
of the aminoglycoside or tetracycline resistance genes
tested. They were also integron negative. The fourth
isolate was also extensively resistant, and was similar to
cluster D regarding resistance genes, except it was lacking
the aph(39)-Ia, the armA and the tetB genes. It also carried
the integron found in cluster D.
Distribution of the clusters among different wards
Isolates originating from the neurology department (except
for a single isolate) and from the paediatric ICU were
susceptible to carbapenems; all other wards were domi-
nated by carbapenem-resistant A. baumannii (P,0.001).
Neurology ICU and paediatric ICU had a significantly
lower number of patients with carbapenem-resistant than
with carbapenem-susceptible A. baumannii (P,0.001–
P50.002 and P50.001–0.03, respectively) as compared
with other wards in pairwise comparisons.
All clusters were dominated by isolates from one or
two wards. Cluster A1 was dominated by isolates from
neurology and from the paediatric ICU; all except one
isolate from cluster A2 originated from the surgery ICU;
the majority of isolates in cluster B were found in the
perinatal ICU; isolates from the first internal ICU
dominated cluster C1; surgery ICU and neurology were
the most frequent source for isolates in cluster C2 and the
pulmonology ICU was the main site for isolates in cluster
D. Cluster distribution among different wards was
significantly different (P,0.0001). Eight of the 17 patients
with armA positive isolates originated from the pulmonol-
ogy ICU (P,0.001–P50.036 in pairwise comparisons with
other wards).
DISCUSSION
Prolonged outbreaks or endemic occurrence by multi-
resistant pathogens is often provoked and maintained by
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selection pressure exerted by antibiotic consumption. This
has been demonstrated in the case of Gram-negative as
well as Gram-positive pathogens (Bergman et al., 2009;
Bronzwaer et al., 2002; Harthug et al., 2000; Rogues et al.,
2007), including several cases of multidrug resistant
Pseudomonas aeruginosa (Rogues et al., 2014; Suarez et al.,
2011), vancomycin-resistant enterococci (Harthug et al.,
2000) and A. baumannii (Paul et al., 2005). Some of these
are associated with clonal spread and maintenance of a
single multiresistant clone (Giannouli et al., 2010), while in
other cases resistance is acquired by the pathogens during
the outbreaks (Corbella et al., 2000; Harthug et al., 2000).
Stopping the outbreaks very frequently necessitated restric-
tion of the usage of the provoker antibiotic, (Suarez et al.,
2011), further confirming the importance of antibiotic
usage as a driving force.
The choice of antibiotic is often motivated by the concern
about drug resistance, leading to increased usage of broad-
spectrum antibiotics, which in turn provokes another
outbreak, creating the resistance spiral. The present study
reports such a situation, when concern about extended-
spectrum beta-lactamase (ESBL) producers provoked by
the consumption of third cephalosporins (unpublished
data) led to increase in carbapenem usage with an approxi-
mately two-year lag, which brought about increased
prevalence and carbapenem resistance in A. baumannii. A
similar relationship has also been reported previously (Goel
et al., 2011; Xu et al., 2013). Increasing colistin use, in turn,
was linked to increasing A. baumannii prevalence, thus
representing a further turn in the resistance spiral, and a
threat to emergence of non-treatable pandrug-resistant A.
baumannii.
Increased prevalence and carbapenem resistance was
directly linked to carbapenem consumption at the ward
level. In the neurology department, where carbapenem
consumption was significantly lower than in any other
department analysed, the majority of A. baumannii isolates
were carbapenem-susceptible, while carbapenem resistance
is a concern in almost all other departments.
The usage of different carbapenems showed different
effects; while imipenem consumption seemed to be less
important as a cause for carbapenem resistance, merope-
nem and especially ertapenem consumption was associated
with increased prevalence of A. baumannii. This corre-
sponds well to the observation that imipenem is slightly
more effective against A. baumannii than meropenem
(MacGowan et al., 1995; Villar et al., 1997). Ertapenem was
also shown as a provoker of carbapenem resistance in P.
aeruginosa, at least in vitro (Vainio et al., 2013). Although
data were inconclusive on the differential role of the
different carbapenems at the ward level, the surgery and
pulmonology departments, where ertapenem is a preferred
carbapenem, are heavily burdened. These data raise the
possibility that not only increased carbapenem consump-
tion is important in the causality of the spread of
carbapenem resistance, but also the pattern of the
particular drugs used may also play an important role.
This issue needs to be addressed by upcoming studies, as
this information may be crucial in optimizing the choice of
carbapenems.
Analysis of the molecular epidemiology revealed that
carbapenem resistance could not be linked to a single
clone; it was rather due to acquisition of BlaOXA-23-like
carbapenemases, similarly to previous findings (Corbella
et al., 2000; Giannouli et al., 2010; Zarrilli et al., 2004).
All resistant clones harboured this gene; moreover, the
resistant isolates in cluster C2 differed from susceptible
isolates in the cluster by the carriage of the blaOXA-23-like
carbapenemase gene. Interestingly, these susceptible iso-
lates originated from, and were exclusively found in,
samples from the neurology department, the ward with the
lowest carbapenem consumption, suggesting that antibiotic
use may have directly facilitated horizontal acquisition of
resistance genes (Couce & Bla´zquez, 2009; Hawkey & Jones,
2009; Valenzuela et al., 2007). The majority of patients
harbouring isolates that carried the aminoglycoside resis-
tance methylase gene armA were patients of the pulmonol-
ogy department, the one with the highest aminoglycoside
consumption, similarly suggesting the role of antibiotic
consumption in horizontal gene transfer. This assumption
is supported by the known genome plasticity of A.
baumannii (Imperi et al., 2011).
Interestingly, most clusters were dominated by isolates
from one or two wards, but many clusters were represented
in multiple wards by a few isolates, suggesting that the
ward-specific strains are continuously transferred to other
wards, creating a polyclonal endemicity pattern.
In conclusion, low carbapenem use was associated with
carbapenem susceptibility even within a single A. bauman-
nii clone, while the spread of carbapenem resistance of A.
baumannii was clearly linked to meropenem and ertape-
nem but not to imipenem consumption. This points to
non-equivalence of even very similar drugs not only in
terms of efficacy but also as provokers of drug resistance.
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